KopranQ4 FY24

Kopran Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹272.66P/E: 33.5Market Cap: ₹1.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

No

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Kopran Limited expects meaningful margin increase and growth from FY'25-26 onwards due to integration of intermediates and new product launches, including US ethanol exports.
  • Sales growth of around 18% to 20% is targeted for FY'25 without considering Panoli operations, aiming for INR730-740 crores in sales and INR100 crores in EBITDA.
  • Panoli plant commercial production is expected to start in Q3 FY'25, contributing to future growth though initial revenues may be limited due to validation and vendor approvals.
  • New products like Edoxaban, Lacosamide, Macitentan, and Penems (Faropenem, Ertapenem) are expected to boost growth.
  • Expansion plans include increasing regulated market presence (US, Europe, UK registrations) which have better margin profiles than domestic and African markets.
  • CDMO business growth is expected after regulatory approvals, possibly starting in 1-2 years.
  • Long-term aspiration is 18%-20% EBITDA margin driven by new high-margin products and export market penetration.

See what Kopran management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • Kopran Limited does not intend to take any additional debt for capex requirements in the near term.
  • The company is not looking at very heavy capex in the next one year.
  • The next major capex is expected at the Panoli plant once environmental clearance is obtained and after the plant runs for about one year.
  • Expansion over the next 3-4 years can be done at existing facilities without acquiring new land parcels.
  • There was no mention of any current or future fundraising plans through equity in the provided transcript.

See what Kopran management said on order book — free account, 30 seconds.

Capex plans

Yes
  • No intention to take additional debt for capex; internal cash flows are expected to suffice for near-term investments.
  • No heavy capex planned in the next one year.
  • Next major capex will be at Panoli site, post-environment clearance, expected likely next fiscal.
  • For next 3-4 years, existing facilities including Panoli can support expansions without needing new land or greenfield projects.
  • Panoli plant commissioning is expected around Q3 FY25, with initial commercial production slated after environmental clearance.
  • R&D center at Panoli is already established; full-scale activity will begin after environmental clearance is obtained.
  • Future CDMO expansion may occur in 1-2 years after approvals.
  • Further brownfield expansions may be made at current sites after Panoli runs for a year.

Track Kopran — get its next earnings analysis in your feed

How does Kopran rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisKopran
Rev 3Mar 1

How does Kopran rank in Pharmaceuticals & Biotechnology?

Compare Kopran against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →